Virtual screening, molecular docking, and molecular dynamics simulation reveal new insights into RNA polymerase inhibition for anti-tuberculosis drug discovery
Source abstract
Abstract
PURPOSE: This study aims to identify potential RNA polymerase (RNAP) inhibitors using a comprehensive computational approach, addressing the challenges in drug discovery related to stability, affinity, and accurate binding predictions. PATIENTS AND METHODS: The research workflow involved virtual screening to narrow down candidate compounds, molecular docking to predict optimal binding poses, molecular dynamics (MD) simulations to evaluate interaction stability over time, and MM-PBSA analysis to calculate binding energies. These steps ensured that only compounds with strong and stable binding profiles were selected for further evaluation. RESULTS: The selected compounds, ZINC001286671821, ZINC000253654686, and ZINC000252693842, demonstrated varying degrees of stability and affinity. MM-PBSA analysis revealed that ZINC000252693842 had the most favourable binding energy at -106.097 ± 24.664 kJ/mol, followed by ZINC001286671821 at -89.201 ± 22.647 kJ/mol, and ZINC000253654686 at -43.832 ± 23.748 kJ/mol. Van der Waals forces were the main contributors to stability, with values of -221.032 ± 27.721 kJ/mol, -187.136 ± 23.796 kJ/mol, and -157.232 ± 19.676 kJ/mol, respectively. These findings confirm the strong binding potential of ZINC000252693842 as an RNAP inhibitor. CONCLUSION: This study highlights the effectiveness of combining virtual screening, molecular docking, MD simulations, and MM-PBSA analysis in identifying promising RNAP inhibitors. The results establish a strong foundation for further experimental validation, advancing the development of effective therapeutic agents targeting RNA polymerase.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Computational Drug Discovery Methods · DNA and Nucleic Acid Chemistry · RNA and protein synthesis mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran
Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Islam Bandung
Department of Pharmacy, Poltekkes Kemenkes Makassar
Research Collaboration Centre for Radiopharmaceuticals Theranostic, National Research and Innovation Agency (BRIN)
References (71)
Show source-provided references
1. 10.1016/j.abd.2021.07.00410.1016/j.abd.2021.07.004 ↗
2. 10.1183/13993003.03300-202010.1183/13993003.03300-2020 ↗
3. 10.33096/gmj.v4i2.10310.33096/gmj.v4i2.103 ↗
4. 10.1016/j.ijid.2020.01.04210.1016/j.ijid.2020.01.042 ↗
5. 10.1016/j.arbres.2022.07.01210.1016/j.arbres.2022.07.012 ↗
6. 10.2147/IDR.S33997210.2147/IDR.S339972 ↗
7. 2024 Global Tuberculosis Report.; ; 2024.
8. 10.3390/life1211177410.3390/life12111774 ↗
9. 10.1128/AAC.02520-1810.1128/AAC.02520-18 ↗
10. 10.3390/ijms2404331310.3390/ijms24043313 ↗
11. 10.1016/S0092-8674(01)00286-010.1016/S0092-8674(01)00286-0 ↗
12. 10.1016/j.molcel.2017.03.00110.1016/j.molcel.2017.03.001 ↗
13. 10.1021/ci049714+10.1021/ci049714+ ↗
14. Bajda M, Panek D, Hebda M, et al. Search for potential cholinesterase inhibitors from the ZINC database by virtual screening method. Acta Pol Pharm - Drug Res. 2015;72(4):737–745.
15. 10.3390/bioengineering1001010010.3390/bioengineering10010100 ↗
16. 10.1016/j.ijbiomac.2019.05.10810.1016/j.ijbiomac.2019.05.108 ↗
17. 10.3390/ph1201003610.3390/ph12010036 ↗
18. 10.2174/138945011766616010112082210.2174/1389450117666160101120822 ↗
19. 10.2174/138955752066620020412315610.2174/1389557520666200204123156 ↗
20. 10.1093/nar/gkv107210.1093/nar/gkv1072 ↗
21. 10.1089/15279160231725035110.1089/152791602317250351 ↗
22. 10.1021/ci049885e10.1021/ci049885e ↗
23. 10.1093/bioinformatics/bts24910.1093/bioinformatics/bts249 ↗
24. 10.1093/nar/gki52410.1093/nar/gki524 ↗
25. 10.1038/nature1648210.1038/nature16482 ↗
26. 10.1038/nature1797010.1038/nature17970 ↗
27. 10.1038/s41586-018-0440-410.1038/s41586-018-0440-4 ↗
28. Jose A Ariza F Lue NZStructural insights into transcriptional regulation by the helicase RECQL5. Published online et al. ; 2025.
29. 10.1038/s42003-021-02088-z10.1038/s42003-021-02088-z ↗
30. 10.1038/s41586-021-03554-810.1038/s41586-021-03554-8 ↗
31. 10.1038/s41467-025-59580-x10.1038/s41467-025-59580-x ↗
32. Frisch MJ Trucks GW Schlegel HB et al. Gaussian16 Wallingford CTGaussian16 (Revision A03). Published online; 2016.
33. 10.1002/wcms.160110.1002/wcms.1601 ↗
34. 10.1056/nejmoa221253710.1056/nejmoa2212537 ↗
35. 10.1016/j.molcel.2018.08.02810.1016/j.molcel.2018.08.028 ↗
36. 10.1093/infdis/jis34110.1093/infdis/jis341 ↗
37. 10.1016/j.bmcl.2007.10.01710.1016/j.bmcl.2007.10.017 ↗
38. 10.1093/nar/gkr32010.1093/nar/gkr320 ↗
39. 10.2147/DDDT.S50765810.2147/DDDT.S507658 ↗
40. BIOVIA. Dassault systèmes BIOVIA, discovery studio modeling environment, release 2017. Dassault Systèmes. 2017; San Diego (Calif).
41. 10.1016/j.bpj.2017.11.32510.1016/j.bpj.2017.11.325 ↗
42. Forli W Halliday S Belew R et al. AutoDock Version 4.2. Citeseer. Published online; 2012.
43. 10.1016/j.molstruc.2022.13247610.1016/j.molstruc.2022.132476 ↗
44. 10.1002/slct.20220172810.1002/slct.202201728 ↗
45. 10.1016/j.scienta.2025.11407810.1016/j.scienta.2025.114078 ↗
46. 10.1038/srep4271710.1038/srep42717 ↗
47. 10.1093/nar/gkac95610.1093/nar/gkac956 ↗
48. 10.1093/nar/gky31810.1093/nar/gky318 ↗
49. Abraham M Hess B D van der S et al. Gromacs - Reference Manual Version 2016.3. SpringerReference. Published online; 2015.
50. 10.1002/jcc.2029110.1002/jcc.20291 ↗
51. 10.1063/1.481236210.1063/1.4812362 ↗
52. 10.1093/bioinformatics/btad35010.1093/bioinformatics/btad350 ↗
53. 10.1021/acs.jcim.5b0030810.1021/acs.jcim.5b00308 ↗
54. 10.1016/j.cpc.2023.10874210.1016/j.cpc.2023.108742 ↗
55. 10.1007/s11222-022-10147-610.1007/s11222-022-10147-6 ↗
56. 10.1021/ci500020m10.1021/ci500020m ↗
57. 10.3389/fmolb.2017.0008710.3389/fmolb.2017.00087 ↗
58. 10.22146/ijc.4732710.22146/ijc.47327 ↗
59. 10.1080/01932691.2023.219593110.1080/01932691.2023.2195931 ↗
60. 10.1246/cl.20075610.1246/cl.200756 ↗
61. 10.1021/acs.accounts.0c0074510.1021/acs.accounts.0c00745 ↗
62. 10.1089/jop.2021.006910.1089/jop.2021.0069 ↗
63. 10.3390/ijms23181023510.3390/ijms231810235 ↗
64. 10.2147/DDDT.S47944710.2147/DDDT.S479447 ↗
65. 10.1080/07391102.2023.221423710.1080/07391102.2023.2214237 ↗
66. 10.1016/j.crstbi.2024.10012510.1016/j.crstbi.2024.100125 ↗
67. 10.1038/nprot.2016.05110.1038/nprot.2016.051 ↗
68. 10.3390/molecules2624745810.3390/molecules26247458 ↗
69. 10.1016/j.compbiolchem.2020.10724110.1016/j.compbiolchem.2020.107241 ↗
70. 10.3390/pathogens1212143310.3390/pathogens12121433 ↗
71. 10.1177/247255521988114810.1177/2472555219881148 ↗